A
Avere Therapeutics
Biotech & Life Sciences · San Francisco, United States
Once-weekly oral therapy for IL-23 inflammatory diseases. MoreLess
Avere Therapeutics is a biotechnology company developing oral therapies for the treatment of IL-23-driven inflammatory diseases. Avere's lead asset, AVR-001, is an oral peptide IL-23 receptor antagonist engineered for once-weekly dosing, with the potential to deliver competitive efficacy in a convenient oral form. Avere is initially advancing AVR-001 in psoriasis, with potential to expand into ulcerative colitis, Crohn's disease, and psoriatic arthritis. The company holds ex-Greater China rights to AVR-001 under a license from Hansoh.
Company overview
Avere Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- —
- Headquarters
- San Francisco, United States
- Employees
- 7
- Open positions
- None listed
- Dealroom signal
- 0.0
- Investment activity
- 1 companies · latest Jul 2026
- Capital deployed
- —
- Preferred round
- ACQUISITION
Valuation & funding
Avere Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Aug 2026 | $500M | $2B | General Atlantic · RTW Investments · Janus Henderson Investors · Venrock Healthcare Capital Partners | ↗ |
| IPO✓Exit | Jul 2026 | $0 | — | Undisclosed | ↗ |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 7 |
Comparisons
Avere Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 Avimer BioAI-optimized protein nanoparticles restoring immune balance. |
United States | Operational | 3 | — | — |
 QRETIX-AIAI-powered platform for accelerated drug discovery. |
— | Operational | |||
 Knoubis BioPhosphatase-targeting biologics for autoimmune disease treatment. |
San Diego, United States | Operational | |||
 I Derm PharmaFirst-in-class oral therapy for moderate-to-severe psoriasis. |
— | Operational | |||
 Bodi HekangTreg-based therapies for autoimmune and inflammatory disorders. |
Shaoxing, China | Operational | |||
 Navigator MedicalBispecific antibody therapies for complex autoimmune diseases. |
Memphis, United States | Operational | |||
 palsideSpecializing in solutions for inflammatory and fibrotic diseases. |
— | Operational | |||
 Beeline MedicinesPrecision therapies for autoimmune and inflammatory diseases. |
Stamford, United States | Operational |
Capital deployed
Avere Therapeutics investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
Avere Therapeutics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Avere Therapeutics has talent and traffic
In the news
Latest news about Avere Therapeutics
Recent press, funding announcements, and product moves mentioning Avere Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Avere Therapeutics
An AI-synthesized read of the highest-engagement posts about Avere Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Avere Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.